SanegeneBio Recognized for Innovation as It Accelerates Development of Novel Small Nucleic Acid Therapeutics

Recently, SANEGENEBIO, Suzhou Shengyin Biomedical Co., Ltd. (hereinafter referred to as "SANEGENEBIO"), has been awarded the recognition of Innovative Small and Medium-sized Enterprise of Suzhou City for the year 2024. Meanwhile, in the 8th Healthcare Investment Excellence Awards 2024 published by Haoyue Capital, SANEGENEBIO was honored with the "Best Innovative Pharmaceutical Company of the Year" award.

The evaluation of innovative small and medium-sized enterprises (SMEs) was formulated by the Ministry of Industry and Information Technology (MIIT), referring to enterprises with a high level of specialization, strong innovation capabilities, and development potential. These enterprises form the foundational strength of high-quality SMEs. The 8th Healthcare Investment Joyful List, released by Holey Capital, an industry investment bank, has been published annually since its inception in 2017. For eight years, it has granted awards to outstanding investment institutions and excellent enterprises in the healthcare sector each year. The initiative aims to create a truly credible and influential investment ranking, set new benchmarks for industry development, and create new opportunities for investment cooperation.

Receiving these two honors not only reflects SANEGENEBIO's high emphasis on independent innovation but also demonstrates that the company's innovative strength and development potential have once again gained widespread recognition.

In the two years since its establishment, SANEGENEBIO has focused on addressing unmet clinical needs. It has built the LEAD™ (Ligand and Enhancer Assisted Delivery) technology platform for the development of novel small nucleic acid drugs and has rapidly advanced multiple core pipelines based on this platform. In the field of metabolic diseases, the company’s drug for treating hypercholesterolemia has entered Phase 1 clinical trials, while the drug co-developed with Innovent Biologics for treating hypertension is expected to enter Phase 1 clinical trials this year. In the field of immune-related diseases, one drug has entered Phase 1 clinical trials, and another is in the IND clinical application stage. At the same time, the company adheres to original innovation in solving key technical challenges. Its research on extrahepatic delivery technology has made breakthrough progress in multiple directions, and it is actively advancing the pipeline construction of extrahepatic delivery projects.

In the future, SANEGENEBIO will continue to focus on addressing unmet global clinical needs, enhance its innovative R&D capabilities, build differentiated core competitiveness, and strive to develop high-potential RNAi drugs as soon as possible for the benefit of patients and their families worldwide.

Editor: Baiji

Disclaimer: This article is a reprint from PharmNet. The images and text are owned by the original author, and the purpose of the reprint is to convey more information, which does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.